Diabetes

John Bel Edwards was elected Governor of Louisiana Saturday after promising to expand Medicaid. Hospitals have been eager to see expansion; in the spring, they supported a fee to pay the state's share once the federal government stops paying 100% of expansion costs.

An Interview with Joslin's George King, MD

The findings suggest that addressing heart patients' social needs is the first step toward getting them to exercise more.

Sequence discovery techniques identified sequences of events that led to gaps in diabetic therapies and were used to identify outreach opportunities aimed at improving medication adherence.

The study population took part in the landmark ORIGIN trial, which evaluated hypoglycemia effects in persons with high CV risk and diabetes.

The action by NICE highlights discussion on both sides of the Atlantic about the cost of PCSK9 inhibitors, which lower LDL cholesterol.

This commentary was adapted from an appearance by the authors at Patient-Centered Diabetes Care, a conference jointly presented by The American Journal of Managed Care and Joslin Diabetes Center.

It is time to regulate laboratory-developed tests that cost Medicare $9.7 billion in the year 2012 alone.

The study suggests treating depression could help combating poor diet and obesity. But in Kentucky, the future of Medicaid expansion is in doubt following the recent election.

Several clinical trials under way are examining whether a new class of therapy approved to treat type 2 diabetes can also treat type 1.

The VEGF inhibitors have been a game-changer in treatment of ocular conditions in diabetes.

A partnership between JDRF and Janssen Pharmaceuticals seeks ways to intercept the disease before it progresses.

Employer policies for access to maximum benefits do not always match those for access to obesity therapy.

Sanofi's vice president of Diabetes Integrated Care discusses the recent collaboration with Google.

St. Peter's Hospital in New Brunswick won the right to a hearing, where New Jersey's largest insurer will have to say why the Catholic hospital was not included in a preferred network set up alongside a major population health initiative.

Results released by Sanofi and Regeneron of their PCSK9 inhibitor were based on prior clinical trials.

The estimated cost per quality-adjusted life year for the PCSK9 drugs is $300,000. How should health plans respond?

Studies at the American Heart Association show very different approaches to exercise for type 2 diabetes patients.

The study presented at the American Heart Association Scientific Session adds to the evidence that SGLT2s are beneficial in treating hypertension.

The study by the well-known health system could not even test some children because they were too large for the MRI machine.

Despite a recommendation by the American Diabetes Association, many patients in the California public mental healthcare system who have severe mental illness and are taking antipsychotic medications were not being screened annually.

More details are revealed on the first diabetes drug shown to have a cardioprotective benefit, but Yale's Silvio Inzucchi was cautious about assuming the effect applies to the entire SGLT2 inhibitor class.

Studies that measure the effect of walkable communities in Canada and taking the train in Japan show that added steps to one's routine can have positive effects on heart health.

A study finds that a commonly prescribed therapy reduces activity in patients with heart failure with preserved ejection fraction.

Eating out has consequences beyond your wallet, according to research from Harvard.